Novo Nordisk faces Capitol Hill scrutiny for pulling Levemir insulin off the market
US Senate aides will meet with Novo Nordisk executives on Tuesday to discuss the consequences of its decision to stop selling one of its long-acting insulins in the country. In April, lawmakers wrote to the company expressing alarm over its decision to permanently discontinue Levemir at the end of 2024.
BELIEBTE BEITRÄGE
Portugal declares risk as wildfires hit the north of the country
September 17, 2024
UK to appoint nature envoy
September 17, 2024
Death tolls rises as Central Europe floods
September 17, 2024
LIVEÜBERTRAGUNG